Psychiatrie-Leitlinien
ClariMed durchsucht psychiatrische Leitlinien von AWMF, DGPPN und internationalen Fachgesellschaften. Quellenbasierte Antworten zu Psychopharmakotherapie, Dosierungen, Wechselwirkungen und akuter Psychiatrie.
Jetzt kostenlos suchenEvidenzbasiert · Kostenlos · Ohne Anmeldung · DSGVO-konform
Das suchen Ärzte wirklich
Anonymisierte Suchanfragen der letzten Woche
“Aufdosierung Valproat bei gleichzeitiger Lamotrigin-Einnahme”
“Antidepressiva in der Stillzeit”
“Paliperidon Depot -- Umstellung auf Risperidon”
“Dissoziative Krampfanfälle -- Therapie akut”
“Akute Psychose -- präklinische Behandlungsoptionen”
Jede Anfrage erhält eine evidenzbasierte Antwort mit direktem Link zur Originalleitlinie.
Probieren Sie es aus
Aufdosierung Valproat bei gleichzeitiger Lamotrigin-Einnahme
Psychiatrie-Leitlinien auf ClariMed
685 Leitlinien mit redaktioneller Zusammenfassung
AWMFS2k-Leitlinie Stationäre Interdisziplinäre Multimodale Schmerztherapie (IMST) bei Kindern und Jugendlichen (S2k)2026CochraneCochrane Review: Diagnostic tests for autism spectrum disorder (ASD) in preschool children2026CochraneCochrane Review: Face-to-face psychoeducation for the parents of people with severe mental illness2026CochraneCochrane Review: Ginkgo biloba for cognitive impairment and dementia2026DGPPNS3-Leitlinie Delir im höheren Lebensalter2026DGPPNS3-Leitlinie Demenzen2026DGPPNS3-Leitlinie Medikamentenbezogene Störungen2026DGPPNS3-Leitlinie Methamphetamin-bezogene Störungen2026DGPPNS3-Leitlinie Umgang mit Suizidalität - Evidenztabellen2026IQWiGIQWiG V25-05: Evidenzrecherche zur S3-Leitlinie Diagnostik und Therapie der Essstörungen2026NICEBipolar disorder: assessment and management2026NICESelf-harm: assessment and management2026NVLNVL Unipolare Depression2026StatPearlsStatPearls: Acute and Chronic Mental Health Trauma2026StatPearlsStatPearls: Acute Stress Disorder2026StatPearlsStatPearls: Adlerian Therapy2026StatPearlsStatPearls: Advancing Patient Care With Biofeedback2026StatPearlsStatPearls: Aggression in Hypothalamic Hamartoma2026StatPearlsStatPearls: Agoraphobia2026StatPearlsStatPearls: Alcohol Withdrawal Syndrome2026StatPearlsStatPearls: Alcohol-Related Psychosis2026StatPearlsStatPearls: Allen Cognitive Level2026StatPearlsStatPearls: Alprazolam2026StatPearlsStatPearls: Alzheimer Disease2026StatPearlsStatPearls: Amitriptyline2026StatPearlsStatPearls: Amoxapine2026StatPearlsStatPearls: Amphetamine-Related Psychiatric Disorders2026StatPearlsStatPearls: Anabolic Steroid Use Disorder2026StatPearlsStatPearls: Anesthetic Considerations in Electroconvulsive Therapy2026StatPearlsStatPearls: Anosognosia2026StatPearlsStatPearls: Antidepressants2026StatPearlsStatPearls: Antisocial Personality Disorder2026StatPearlsStatPearls: Anxiety2026StatPearlsStatPearls: Anxiolytics and Sedative-Hypnotics Toxicity2026StatPearlsStatPearls: Aripiprazole2026StatPearlsStatPearls: Atomoxetine2026StatPearlsStatPearls: Atypical Antipsychotic Effect on Bone Mineral Density2026StatPearlsStatPearls: Auditory Hallucinations2026StatPearlsStatPearls: Autism Spectrum Disorder2026StatPearlsStatPearls: Avoidant Personality Disorder2026StatPearlsStatPearls: Behavioral and Psychological Symptoms in Dementia2026StatPearlsStatPearls: Behavioral Therapy2026StatPearlsStatPearls: Benzodiazepines2026StatPearlsStatPearls: Benztropine2026StatPearlsStatPearls: Binge Eating Disorder2026StatPearlsStatPearls: Bipolar Disorder2026StatPearlsStatPearls: Body Dysmorphic Disorder2026StatPearlsStatPearls: Borderline Personality Disorder2026StatPearlsStatPearls: Brief Psychotic Disorder2026StatPearlsStatPearls: Bupropion2026StatPearlsStatPearls: Buspirone2026StatPearlsStatPearls: Caffeine Withdrawal2026StatPearlsStatPearls: Cannabis Use Disorder2026StatPearlsStatPearls: Capgras Syndrome2026StatPearlsStatPearls: Catatonia2026StatPearlsStatPearls: Change in Mental Status2026StatPearlsStatPearls: Child Sexual Abuse2026StatPearlsStatPearls: Chlorpromazine2026StatPearlsStatPearls: Chronic Insomnia2026StatPearlsStatPearls: Citalopram2026StatPearlsStatPearls: Claustrophobia2026StatPearlsStatPearls: Clomipramine2026StatPearlsStatPearls: Clonazepam2026StatPearlsStatPearls: Clozapine2026StatPearlsStatPearls: Cognitive Behavior Therapy2026StatPearlsStatPearls: Conduct Disorder2026StatPearlsStatPearls: Coprolalia2026StatPearlsStatPearls: Cyclothymic Disorder2026StatPearlsStatPearls: Deep Brain Stimulation2026StatPearlsStatPearls: Delirium2026StatPearlsStatPearls: Delusional Misidentification Syndrome2026StatPearlsStatPearls: Delusions of Parasitosis2026StatPearlsStatPearls: Dependent Personality Disorder2026StatPearlsStatPearls: Depression2026StatPearlsStatPearls: Depression (Nursing)2026StatPearlsStatPearls: Depression in Children2026StatPearlsStatPearls: Depressive Cognitive Disorders2026StatPearlsStatPearls: Desipramine2026StatPearlsStatPearls: Desvenlafaxine2026StatPearlsStatPearls: Differentiating Delirium Versus Dementia in Older Adults2026StatPearlsStatPearls: Dissociative Identity Disorder2026StatPearlsStatPearls: Doxepin2026StatPearlsStatPearls: Duloxetine2026StatPearlsStatPearls: Electroconvulsive Therapy2026StatPearlsStatPearls: Escitalopram2026StatPearlsStatPearls: Exploding Head Syndrome2026StatPearlsStatPearls: Extrapyramidal Side Effects2026StatPearlsStatPearls: Fatal Familial Insomnia2026StatPearlsStatPearls: Florida: Domestic Violence2026StatPearlsStatPearls: Fluoxetine2026StatPearlsStatPearls: Fluphenazine2026StatPearlsStatPearls: Frontal Lobe Syndrome2026StatPearlsStatPearls: Gender Dysphoria2026StatPearlsStatPearls: Generalized Anxiety Disorder2026StatPearlsStatPearls: Generalized Anxiety Disorder (Nursing)2026StatPearlsStatPearls: Grief and Prolonged Grief Disorder2026StatPearlsStatPearls: Grief Support Following In-Hospital Deaths2026StatPearlsStatPearls: Haloperidol2026StatPearlsStatPearls: Histrionic Personality Disorder2026StatPearlsStatPearls: Huntington Disease2026StatPearlsStatPearls: ICU Delirium2026StatPearlsStatPearls: Illness Anxiety Disorder2026StatPearlsStatPearls: Imipramine2026StatPearlsStatPearls: Implicit Bias2026StatPearlsStatPearls: Imposter Phenomenon2026StatPearlsStatPearls: Intellectual Disability2026StatPearlsStatPearls: Kluver-Bucy Syndrome2026StatPearlsStatPearls: La Belle Indifference2026StatPearlsStatPearls: Lamotrigine2026StatPearlsStatPearls: Late-Life Depression2026StatPearlsStatPearls: Lewy Bodies2026StatPearlsStatPearls: Lewy Body Dementia2026StatPearlsStatPearls: Lifestyle Mental Wellbeing for the Primary Care Visit2026StatPearlsStatPearls: Lithium2026StatPearlsStatPearls: Lorazepam2026StatPearlsStatPearls: Lumateperone2026StatPearlsStatPearls: Lurasidone2026StatPearlsStatPearls: Major Depressive Disorder2026StatPearlsStatPearls: Major Depressive Disorder (Nursing)2026StatPearlsStatPearls: Major Neurocognitive Disorder (Dementia)2026StatPearlsStatPearls: Major Neurocognitive Disorder (Dementia) (Nursing)2026StatPearlsStatPearls: Mania2026StatPearlsStatPearls: MAO Inhibitors2026StatPearlsStatPearls: Mental Health Challenges in Caring for American Indians and Alaska Natives2026StatPearlsStatPearls: Methylphenidate2026StatPearlsStatPearls: Mild Cognitive Impairment2026StatPearlsStatPearls: Mirtazapine2026StatPearlsStatPearls: Monoamine Oxidase Inhibitors (MAOIs)2026StatPearlsStatPearls: Mood Disorder2026StatPearlsStatPearls: Mood Stabilizers2026StatPearlsStatPearls: Neuroleptic Agent Toxicity2026StatPearlsStatPearls: Neuroleptic Medications2026StatPearlsStatPearls: Neuromodulation Surgery for Psychiatric Disorders2026StatPearlsStatPearls: Night Eating Syndrome2026StatPearlsStatPearls: Nortriptyline2026StatPearlsStatPearls: Obsessive-Compulsive Disorder2026StatPearlsStatPearls: Olanzapine2026StatPearlsStatPearls: Opioid Use Disorder: Evaluation and Management2026StatPearlsStatPearls: Oxazepam2026StatPearlsStatPearls: Panic Disorder2026StatPearlsStatPearls: Paranoid Personality Disorder2026StatPearlsStatPearls: Paroxetine2026StatPearlsStatPearls: Patient Restraint and Seclusion2026StatPearlsStatPearls: Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS)2026StatPearlsStatPearls: Perinatal Depression2026StatPearlsStatPearls: Persistent Depressive Disorder2026StatPearlsStatPearls: Persistent Postural-Perceptual Dizziness2026StatPearlsStatPearls: Personality Disorder2026StatPearlsStatPearls: Phencyclidine Toxicity2026StatPearlsStatPearls: Phenelzine2026StatPearlsStatPearls: Phenothiazine2026StatPearlsStatPearls: Physiology, Serotonin2026StatPearlsStatPearls: Pimavanserin2026StatPearlsStatPearls: Postpartum Psychosis2026StatPearlsStatPearls: Posttraumatic Stress Disorder2026StatPearlsStatPearls: Premenstrual Dysphoric Disorder2026StatPearlsStatPearls: Protriptyline2026StatPearlsStatPearls: Provider Burnout2026StatPearlsStatPearls: Psychiatric Complications of Bariatric Surgery2026StatPearlsStatPearls: Psychoanalytic Therapy2026StatPearlsStatPearls: Psychodynamic Therapy2026StatPearlsStatPearls: Psychogenic Nonepileptic Seizures2026StatPearlsStatPearls: Psychological Issues Associated With Obesity2026StatPearlsStatPearls: Psychosis2026StatPearlsStatPearls: Psychosis (Nursing)2026StatPearlsStatPearls: Quetiapine2026StatPearlsStatPearls: Rapid Eye Movement Sleep Behavior Disorder2026StatPearlsStatPearls: Reactive Attachment Disorder2026StatPearlsStatPearls: Recognizing Alcohol and Drug Impairment in the Workplace in Florida2026StatPearlsStatPearls: Relaxation Techniques2026StatPearlsStatPearls: REM Rebound Effect2026StatPearlsStatPearls: Risperidone2026StatPearlsStatPearls: Rivastigmine2026StatPearlsStatPearls: Schizoid Personality Disorder2026StatPearlsStatPearls: Schizophrenia2026StatPearlsStatPearls: Schizotypal Personality Disorder2026StatPearlsStatPearls: School Refusal2026StatPearlsStatPearls: Screening for Depression and Suicide in Children2026StatPearlsStatPearls: Seasonal Affective Disorder2026StatPearlsStatPearls: Second Victim Syndrome2026StatPearlsStatPearls: Selective Serotonin Reuptake Inhibitor Toxicity2026StatPearlsStatPearls: Selective Serotonin Reuptake Inhibitors2026StatPearlsStatPearls: Sensory and Perceptual Alterations2026StatPearlsStatPearls: Separation Anxiety Disorder2026StatPearlsStatPearls: Sertraline2026StatPearlsStatPearls: Shared Psychotic Disorder2026StatPearlsStatPearls: Sleep Deprivation2026StatPearlsStatPearls: Social Anxiety Disorder2026StatPearlsStatPearls: Specific Phobia2026StatPearlsStatPearls: Stress Management2026StatPearlsStatPearls: Substance-Induced Mood Disorders2026StatPearlsStatPearls: Suicidal Ideation2026StatPearlsStatPearls: Suicide: Assessment and Management2026StatPearlsStatPearls: Temazepam2026StatPearlsStatPearls: Thioridazine2026StatPearlsStatPearls: Tourette Syndrome and Other Tic Disorders2026StatPearlsStatPearls: Tranylcypromine2026StatPearlsStatPearls: Trauma-Informed Therapy2026StatPearlsStatPearls: Trazodone2026StatPearlsStatPearls: Tricyclic Antidepressant Toxicity2026StatPearlsStatPearls: Tricyclic Antidepressants2026StatPearlsStatPearls: Vagus Nerve Stimulator2026StatPearlsStatPearls: Valproic Acid2026StatPearlsStatPearls: Venlafaxine2026StatPearlsStatPearls: Veteran and Military Mental Health Issues2026StatPearlsStatPearls: Washington State Suicide Prevention and Awareness2026StatPearlsStatPearls: Ziprasidone2026AkdÄAkdÄ: Information des BfArM zum Lieferengpass von Zypadhera (Olanzapinpamoat-Monohydrat Pulver und Lösungsmittel zur Herstellung einer2025AkdÄAkdÄ: Rote-Hand-Brief zu Clozapin: Überarbeitete Empfehlungen zur routinemäßigen Blutbildkontrolle im Hinblick auf das Risiko einer AgranulozytoseDrug2025AkdÄAkdÄ: Rote-Hand-Brief zu Finasterid, Dutasterid: Neue Maßnahmen zur Minimierung des Risikos für Suizidgedanken2025APAJoint Clinical Practice Guideline on Benzodiazepine Tapering2025ATSTreatment of Nicotine Use in Adolescents Under 18 Years of Age: An Official American Thoracic Society Clinical Practice Guideline2025AWMFAWMF 038-020: S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen2025AWMFDelir und Verwirrtheitszustände inklusive Alkoholentzugsdelir2025AWMFDepression bei Menschen mit Querschnittlähmung: Besonderheiten in der Diagnostik und Behandlung2025AWMFDiagnostik und Behandlung von Zwangsstörungen im Kindes- und Jugendalter2025AWMFNicht-alkoholische Fettlebererkrankungen2025AWMFNotfallpsychiatrie2025AWMFS2k-Leitlinie Prävention, Durchführung und Nachsorge von freiheitsentziehenden Unterbringungen und Maßnahmen in Kliniken für Kinder- und Jugendpsychiatrie und -psychotherapie2025AWMFS3-Leitlinie Seltene Lebererkrankungen – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter (LeiSe LebEr) - Living Guideline2025AWMFS3-Leitlinie Seltene Lebererkrankungen – Genetisch-cholestatische Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter (LeiSe LebEr)2025AWMFS3-Leitlinie Demenzen (AWMF 038-013, 2025)2025AWMFS3-Leitlinie Schizophrenie (AWMF 038-009, 2025)2025BfArMAtomoxetin: Neue Warnhinweise zu Serotoninsyndrom und Mordgedanken2025CochraneCochrane Review: Acupuncture for insomnia in people with cancer2025CochraneCochrane Review: Antidepressants versus placebo for generalised anxiety disorder (GAD)2025CochraneCochrane Review: Atypical antipsychotics for autism spectrum disorder: a network meta-analysis2025CochraneCochrane Review: Beck Anxiety Inventory (BAI) for detecting anxiety disorders in adults2025CochraneCochrane Review: Breastfeeding interventions for preventing postpartum depression2025CochraneCochrane Review: Brexanolone, zuranolone and related neurosteroid GABA(A) receptor positive allosteric modulators for postnatal depression2025CochraneCochrane Review: Cognitive behavioural therapy for insomnia in people with cancer2025CochraneCochrane Review: Combined pharmacological and psychosocial interventions for alcohol use disorder2025CochraneCochrane Review: Generalized Anxiety Disorder 7-item (GAD-7) and 2-item (GAD-2) scales for detecting anxiety disorders in adults2025CochraneCochrane Review: Home visiting for postpartum depression2025CochraneCochrane Review: Hospital Anxiety and Depression Scale Anxiety subscale (HADS-A) for detecting anxiety disorders in adults2025CochraneCochrane Review: Interventions for helping people recognise early signs of recurrence in bipolar disorder2025CochraneCochrane Review: Lurasidone versus typical antipsychotics for schizophrenia2025CochraneCochrane Review: Music-based therapeutic interventions for people with dementia2025CochraneCochrane Review: Opioid agonist therapy for opioid use disorder in primary versus specialty care2025CochraneCochrane Review: Pharmacotherapies for cannabis use disorder2025CochraneCochrane Review: Post-incident debriefing for people with schizophrenia after coercive measures2025CochraneCochrane Review: Psychological interventions for treatment of inflammatory bowel disease2025CochraneCochrane Review: State-Trait Anxiety Inventory (STAI) for detecting anxiety disorders in adults2025CochraneCochrane Review: Sustained-release naltrexone for opioid dependence2025CochraneCochrane Review: Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia2025DEGAMAWMF 053-002: S3-Leitlinie Müdigkeit2025DGPPNS2k-Leitlinie Begutachtung psychischer und psychosomatischer Störungen - Interessenkonflikte2025DGPPNS3-Leitlinie Behandlung cannabisbezogener Störungen2025DGPPNS3-Leitlinie Schizophrenie2025DGPPNS3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen - Tabellenband2025DGPPNS3-Leitlinie/NVL Unipolare Depression - Evidenzbericht2025DGPPNS3-Leitlinie/NVL Unipolare Depression - Interessenkonflikte2025Gemeinsamer Bundesausschuss (G-BA)DMP-Anforderungen-Richtlinie (G-BA) - Konsolidierte Fassung2025IQWiGIQWiG V24-12: Evidenzrecherche zur S3-Leitlinie Definition, Ursachen, Diagnostik und Therapie des Fibromyalgiesyndroms2025NICEAutism spectrum disorder in adults2025NICEAutism spectrum disorder in under 19s: support2025NICEGambling-related harms2025NICEMedicines associated with dependence2025WHOGuidance on mental health policy and strategic action plans: Module 4. Country case scenarios2025WHOWHO guideline on HIV service delivery2025Addiction PsychiatryPTSD Severity Influence on Return to Substance Use After Treatment2024AkdÄAkdÄ Bekanntgabe: Psychiatrische und sexuelle Nebenwirkungen von Finasterid („UAW-News International")2024AkdÄAkdÄ: „UAW-News International“: Psychiatrische und sexuelle Nebenwirkungen von Finasterid2024AkdÄAkdÄ: Information zu Aripiprazol: pathologisches Spielen2024AkdÄAkdÄ: Information zu Fluorchinolonen: suizidale Gedanken und suizidales Verhalten2024AkdÄAkdÄ: Information zu Pregabalin und Gabapentin: Berichterstattung in den Medien zu Todesfällen2024American Society of Addiction MedicineManagement of Amphetamine and Methamphetamine Use Disorders: Systematic Review2024AWMFS3-Leitlinie Methamphetamin-Störungen (AWMF 038-024)2024AWMFS3-Leitlinie Opioidbezogene Störungen2024AWMFS3-Leitlinie PTBS (AWMF 155-001)2024AWMFS3-Leitlinie Suizidalität Kindes-/Jugendalter (AWMF 028-031)2024AWMFS3-Leitlinie Tabakkonsum (AWMF 076-006)2024AWMFS3-Leitlinie Zwangsstörungen (AWMF 038-017)2024BfArMValproat: Potenzielles Risiko für neurologische Entwicklungsstörungen bei Kindern von Vätern, die valproathaltige Arzneimittel einnehmen2024CochraneCochrane Review: Cognitive behavioural therapy added to standard care for first-episode and recent-onset psychosis2024CochraneCochrane Review: Cognitive behavioural therapy and third-wave approaches for anxiety and related disorders in older people2024CochraneCochrane Review: Cognitive behavioural therapy without medication for schizophrenia2024CochraneCochrane Review: Collaborative care approaches for people with severe mental illness2024CochraneCochrane Review: Diagnostic test accuracy of self-administered cognitive assessment tools for dementia2024CochraneCochrane Review: Disulfiram for the treatment of cocaine dependence2024CochraneCochrane Review: Early pharmacological interventions for prevention of post-traumatic stress disorder (PTSD) in individuals experiencing acute traumatic stress symptoms2024CochraneCochrane Review: Exergaming for dementia and mild cognitive impairment2024CochraneCochrane Review: Eye movement desensitisation and reprocessing for survivors of life-threatening medical events2024CochraneCochrane Review: Factors that influence participation in physical activity for people with bipolar disorder: a synthesis of qualitative evidence2024CochraneCochrane Review: Family-based interventions versus standard care for people with schizophrenia2024CochraneCochrane Review: Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment2024CochraneCochrane Review: Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders2024CochraneCochrane Review: Non-pharmacological interventions for improving language and communication in people with primary progressive aphasia2024CochraneCochrane Review: Omega-3 fatty acid supplementation for depression in children and adolescents2024CochraneCochrane Review: Parenteral medication for the management of acute severe behavioural disturbance (ASBD) in the emergency department2024CochraneCochrane Review: Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases2024CochraneCochrane Review: Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises2024CochraneCochrane Review: Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation2024CochraneCochrane Review: Psychosocial interventions for stimulant use disorder2024CochraneCochrane Review: Repetitive transcranial magnetic stimulation for post-traumatic stress disorder in adults2024CochraneCochrane Review: Risk assessment for aggressive behaviour in schizophrenia2024CochraneCochrane Review: Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder2024CochraneCochrane Review: Transitional discharge interventions for people with schizophrenia2024DEGAMAWMF 053-024: S3-Leitlinie Hausärztliche Versorgung2024DGPPNS2k-Leitlinie Einwilligung von Menschen mit Demenz in medizinische Maßnahmen - Interessenkonflikte2024G-BAG-BA Nutzenbewertung: Daridorexant (Erneute Bewertung nach Änderung der Anlage III AM-RL: Schlafstörungen)2024Heart and Stroke Foundation of CanadaCanadian Stroke Best Practice Recommendations: Vascular Cognitive Impairment (7th Edition, 2024)2024IQWiGIQWiG A19-04: Melatonin (Schlafstörungen) - Nutzenbewertung gemäß §35a SGB V2024IQWiGIQWiG A19-47: Melatonin (Schlafstörungen bei Kindern und Jugendlichen mit Autismus-Spektrum-Störung und / oder Smith-Magenis-Syndrom) - Addendum zum Auftrag A19-042024IQWiGIQWiG A22-34: Nutzenbewertung von Bupropion, Cytisin, Nicotin und Vareniclin zur Tabakentwöhnung bei schwerer Tabakabhängigkeit 2024IQWiGIQWiG HT22-02 : Generalisierte Angststörung: Helfen Apps Betroffenen bei der Bewältigung ihrer Erkrankung?2024NICECG103: Delirium: prevention, diagnosis and management2024NICECG170: Autism spectrum disorder in under 19s2024NICECG178: Psychosis and schizophrenia in adults2024NICECG185: Bipolar disorder: assessment and management2024NICENG116: Post-traumatic stress disorder2024NICENG134: Anxiety disorders2024NICENG141: Suicidal thoughts and behaviour: assessment, treatment and management2024NICENG194: ADHD: diagnosis and management2024NICENG222: Depression in adults: treatment and management2024NICENG66: Mental health of adults in contact with the criminal justice system2024NICENG87: Eating disorders: recognition and treatment2024NICEPhysical activity and the environment2024NICESocial work with adults experiencing complex needs2024RACGPPreamble2024RACGPPrescribing drugs of dependence in general practice2024WHOFacilitation manual: psychological first aid during Ebola virus disease outbreaks, 2nd edition2024WHOMental health of children and young people: service guidance2024APAAPA Practice Guidelines for the Treatment of Eating Disorders2023AWMFS3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus2023AWMFNationale VersorgungsLeitlinie Unipolare Depression (NVL, 2023)2023CochraneCochrane Review: Acetylcholinesterase inhibitors for autistic spectrum disorders2023CochraneCochrane Review: Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment2023CochraneCochrane Review: Antidepressants for the treatment of depression in people with cancer2023CochraneCochrane Review: Baclofen for alcohol use disorder2023CochraneCochrane Review: Behavioural and cognitive-behavioural interventions for outwardly directed aggressive behaviour in people with intellectual disabilities2023CochraneCochrane Review: Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia2023CochraneCochrane Review: Cognitive rehabilitation for people with mild to moderate dementia2023CochraneCochrane Review: Dance movement therapy for dementia2023CochraneCochrane Review: Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatment2023CochraneCochrane Review: Magnetic seizure therapy for people with schizophrenia2023CochraneCochrane Review: Mental Health First Aid as a tool for improving mental health and well-being2023CochraneCochrane Review: Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis2023CochraneCochrane Review: Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)2023CochraneCochrane Review: Motivational interviewing for substance use reduction2023CochraneCochrane Review: Non-pharmacological interventions for sleep disturbances in people with dementia2023CochraneCochrane Review: Personally tailored activities for improving psychosocial outcomes for people with dementia in long-term care2023CochraneCochrane Review: Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)2023CochraneCochrane Review: Pharmacological treatments in panic disorder in adults: a network meta-analysis2023CochraneCochrane Review: Pharmacological, non-invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke2023CochraneCochrane Review: Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents2023CochraneCochrane Review: Primary-level and community worker interventions for the prevention of mental disorders and the promotion of well-being in low- and middle-income countries2023CochraneCochrane Review: Psychological interventions for depression in adolescent and adult congenital heart disease2023CochraneCochrane Review: Psychological interventions for women with non-metastatic breast cancer2023CochraneCochrane Review: Psychological therapies delivered remotely for the management of chronic pain (excluding headache) in adults2023CochraneCochrane Review: Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries2023CochraneCochrane Review: Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa2023DGPPNS3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung2023DGPPNS3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung - Interessenkonflikte2023DGPPNS3-Leitlinie/NVL Unipolare Depression - Was ist neu?2023G-BAG-BA Nutzenbewertung: Esketamin (Neubewertung nach Fristablauf: Depression, therapieresistent, in Kombination mit SSRI oder SNRI)2023IQWiGIQWiG A23-18: Esketamin (therapieresistente Major Depression) – Nutzenbewertung gemäß § 35a SGB V2023IQWiGIQWiG A23-75: Esketamin (therapieresistente Major Depression) – Addendum zum Auftrag A23-182023IQWiGIQWiG HT21-02: Burnout: Kann Yoga bei der Bewältigung helfen? 2023IQWiGIQWiG V22-01: Leitliniensynopse für die Aktualisierung des DMP Depression 2023Leitlinienprogramm OnkologieS3-Leitlinie Psychoonkologie v2.0 (Leitlinienprogramm Onkologie, 2023)2023NICEGeneralised anxiety disorder and panic disorder in adults: management2023SIGNSIGN 168: Assessment, Diagnosis, Care and Support for People with Dementia and Their Carers2023SIGNSIGN 169: Perinatal mental health conditions2023USPSTFScreening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement.2023USPSTFScreening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement.2023USPSTFUSPSTF Recommendation: Screening for Depression in Adults2023USPSTFUSPSTF: Anxiety Disorders in Adults: Screening (Grade B, 2023)2023USPSTFUSPSTF: Anxiety Disorders in Adults: Screening (Grade B)2023USPSTFUSPSTF: Depression and Suicide Risk in Adults: Screening (Grade B, 2023)2023WHOMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders2023WHOMental health, human rights and legislation: guidance and practice2023WHOWHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions2023WHOWHO Guide to Mental Health in Primary Care (Depression)2023WHOWHO Guidelines on Management of Substance Abuse2023WHOWHO guidelines on parenting interventions to prevent maltreatment and enhance parent–child relationships with children aged 0–17 years: web annex2023WHOWHO Mental Health Gap Action Programme (mhGAP) Guidelines2023WHOWHO operational handbook on tuberculosis: module 6: tuberculosis and comorbidities: mental health conditions2023WHOWHO EML 2023: Section 13 - Psychotherapeutic Medicines2023AWMFS3-Leitlinie Borderline-Persönlichkeitsstörung2022CochraneCochrane Review: Algorithm-based pain management for people with dementia in nursing homes2022CochraneCochrane Review: Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia2022CochraneCochrane Review: Antipsychotic dose reduction compared to dose continuation for people with schizophrenia2022CochraneCochrane Review: Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia2022CochraneCochrane Review: Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms2022CochraneCochrane Review: Cognitive behavioural therapy (group) for schizophrenia2022CochraneCochrane Review: Control interventions in randomised trials among people with mental health disorders2022CochraneCochrane Review: Diagnostic test accuracy of remote, multidomain cognitive assessment (telephone and video call) for dementia2022CochraneCochrane Review: Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD)2022CochraneCochrane Review: Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults2022CochraneCochrane Review: Listening to music for insomnia in adults2022CochraneCochrane Review: Memantine for autism spectrum disorder2022CochraneCochrane Review: Music therapy for autistic people2022CochraneCochrane Review: Music therapy for people with substance use disorders2022CochraneCochrane Review: Opioid agonist treatment for people who are dependent on pharmaceutical opioids2022CochraneCochrane Review: Overall prognosis of preschool autism spectrum disorder diagnoses2022CochraneCochrane Review: Pharmaceutical interventions for emotionalism after stroke2022CochraneCochrane Review: Pharmacological interventions for people with borderline personality disorder2022CochraneCochrane Review: Pharmacological interventions for prevention of weight gain in people with schizophrenia2022CochraneCochrane Review: Pharmacological interventions for the treatment of disordered and problem gambling2022CochraneCochrane Review: Pharmacotherapy for post traumatic stress disorder (PTSD)2022CochraneCochrane Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment2022CochraneCochrane Review: Shared decision-making interventions for people with mental health conditions2022CochraneCochrane Review: Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy2022DGPPNS3-Leitlinie Borderline-Persönlichkeitsstörung2022DGPPNS3-Leitlinie Kindesmisshandlung, -missbrauch und -vernachlässigung (Kinderschutzleitlinie)2022DGPPNS3-Leitlinie Zwangsstörungen2022G-BAG-BA Nutzenbewertung: Daridorexant (Schlafstörungen, Anwendung bis zu 4 Wochen)2022IQWiGIQWiG HT19-04: Depressionen bei Kindern und Jugendlichen: Führt Psychotherapie im Vergleich zu anderen Therapien zu besseren Ergebnissen?2022IQWiGIQWiG HT20-02: Herzerkrankung bei Kindern: Können Kinder durch eine psychologische Begleitung bei der Bewältigung ihrer Krankheit unterstützt werden?2022IQWiGIQWiG V21-06: Evidenzrecherche: S3-Leitlinie Cannabisbezogene Störungen2022NICEDepression in adults: treatment and management2022NICENG212: Mental wellbeing at work2022NICENG223: Social, emotional and mental wellbeing in primary and secondary education2022NICENICE Guideline on Self-Harm Assessment2022NICENICE NG222: Depression in adults: treatment and management2022NICENICE NG225: Self-harm: assessment, management and preventing recurrence2022NVLS3-Leitlinie Nationale VersorgungsLeitlinie Unipolare Depression2022SIGNSIGN 164: Eating Disorders2022USPSTFScreening for Anxiety in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2022USPSTFScreening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2022WHOGuidelines on mental health at work2022WHOMental health at work: policy brief2022WHOWHO Guidelines on Mental Health at Work2022ACEPClinical Policy: Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the ED2021AWMFAWMF 021-020: S3-Leitlinie Divertikelkrankheit / Divertikulitis2021AWMFS3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen2021AWMFS3-Leitlinie Behandlung von Angststörungen (AWMF 051-028, 2021)2021AWMFS3-Leitlinie Alkoholbezogene Störungen (AWMF 076-001, 2021)2021CochraneCochrane Review: Anticholinergic drugs and dementia: time for transparency in the face of uncertainty2021CochraneCochrane Review: Antidepressant treatment for postnatal depression2021CochraneCochrane Review: Antidepressants for functional abdominal pain disorders in children and adolescents2021CochraneCochrane Review: Antidepressants for people with epilepsy and depression2021CochraneCochrane Review: Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia2021CochraneCochrane Review: Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults2021CochraneCochrane Review: Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)2021CochraneCochrane Review: Cannabinoids for the treatment of dementia2021CochraneCochrane Review: Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis2021CochraneCochrane Review: Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment2021CochraneCochrane Review: Effectiveness of psychosocial interventions for reducing parental substance misuse2021CochraneCochrane Review: Humour-based interventions for people with schizophrenia2021CochraneCochrane Review: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults2021CochraneCochrane Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the detection of dementia within a secondary care setting2021CochraneCochrane Review: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early detection of dementia across a variety of healthcare settings2021CochraneCochrane Review: Internet-based cognitive and behavioural therapies for post-traumatic stress disorder (PTSD) in adults2021CochraneCochrane Review: Interventions for fear of childbirth including tocophobia2021CochraneCochrane Review: Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries2021CochraneCochrane Review: Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder2021CochraneCochrane Review: Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder2021CochraneCochrane Review: Lamotrigine in the maintenance treatment of bipolar disorder2021CochraneCochrane Review: Magnetic seizure therapy for treatment-resistant depression2021CochraneCochrane Review: Medications for daytime sleepiness in individuals with idiopathic hypersomnia2021CochraneCochrane Review: Mindfulness-based interventions for substance use disorders2021CochraneCochrane Review: Mini-Cog for the detection of dementia within a primary care setting2021CochraneCochrane Review: Mini-Cog for the detection of dementia within a secondary care setting2021CochraneCochrane Review: Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)2021CochraneCochrane Review: Montreal Cognitive Assessment for the detection of dementia2021CochraneCochrane Review: Music interventions for improving psychological and physical outcomes in people with cancer2021CochraneCochrane Review: New generation antidepressants for depression in children and adolescents: a network meta-analysis2021CochraneCochrane Review: Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients2021CochraneCochrane Review: Omega-3 fatty acids for depression in adults2021CochraneCochrane Review: Palliative care interventions in advanced dementia2021CochraneCochrane Review: Parenting interventions for people with schizophrenia or related serious mental illness2021CochraneCochrane Review: Pharmacological treatment for psychotic depression2021CochraneCochrane Review: Pharmacotherapy for trichotillomania2021CochraneCochrane Review: Pre-deployment programmes for building resilience in military and frontline emergency service personnel2021CochraneCochrane Review: Prevention of depression in adults with long-term physical conditions2021CochraneCochrane Review: Primary-level worker interventions for the care of people living with mental disorders and distress in low- and middle-income countries2021CochraneCochrane Review: Prognostic models for predicting relapse or recurrence of major depressive disorder in adults2021CochraneCochrane Review: Psychological and pharmacological interventions for depression in patients with coronary artery disease2021CochraneCochrane Review: Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes2021CochraneCochrane Review: Remotely delivered information, training and support for informal caregivers of people with dementia2021CochraneCochrane Review: Second-generation antidepressants for treatment of seasonal affective disorder2021CochraneCochrane Review: Selective serotonin re-uptake inhibitors for premature ejaculation in adult men2021CochraneCochrane Review: Smoking cessation for improving mental health2021CochraneCochrane Review: The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder2021CochraneCochrane Review: Video games for people with schizophrenia2021CochraneCochrane Review: Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia2021DGPPNS3-Leitlinie Autismus-Spektrum-Störungen im Kindes-, Jugend- und Erwachsenenalter2021DGPPNS3-Leitlinie Posttraumatische Belastungsstörung (PTBS)2021DGPPNS3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung2021DGPPNS3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen - Tabellenband - Interessenkonflikte2021G-BAG-BA Nutzenbewertung: Esketamin (Bekannter Wirkstoff mit neuem Unterlagenschutz: Depression, akute Kurzzeitbehandlung, Kombinationstherapie)2021G-BAG-BA Nutzenbewertung: Esketamin (Bekannter Wirkstoff mit neuem Unterlagenschutz: Depression, therapieresistent, in Kombination mit SSRI oder SNRI)2021G-BAG-BA Nutzenbewertung: Eszopiclon (Schlafstörungen)2021IQWiGIQWiG A21-24: Esketamin (Depression) - Nutzenbewertung gemäß § 35a SGB V2021IQWiGIQWiG A21-25: Esketamin (Depression, Akutbehandlung) - Nutzenbewertung gemäß § 35a SGB V2021IQWiGIQWiG V20-03: Evidenzrecherche S3-Leitlinie Demenzen2021IQWiGIQWiG V20-07: Evidenzrecherche S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen - Insomnie bei Erwachsenen2021NICENG205: Looked-after children and young people2021NICENICE Guideline on Autism Spectrum Disorder2021USPSTFInterventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement.2021WHOGuidance on community mental health services: Promoting person-centred and rights-based approaches2021WHOMental health crisis services: promoting person-centred and rights-based approaches2021WHOMental health investment case: a guidance note2021WHOTeacher's Guide2021AkdÄAkdÄ: Information des BfArM zu Hydroxychloroquin und Chloroquin: Psychiatrische Störungen.2020ATSInitiating Pharmacologic Treatment in Tobacco-Dependent Adults: An Official American Thoracic Society Clinical Practice Guideline2020AWMFS3-Leitlinie Medikamentenbezogene Störungen2020BfArMHydroxychloroquin und Chloroquin: Psychiatrische Störungen2020CochraneCochrane Review: Alcoholics Anonymous and other 12-step programs for alcohol use disorder2020CochraneCochrane Review: An overview of systematic reviews on mental health promotion, prevention, and treatment of common mental disorders for refugees, asylum seekers, and internally displaced persons2020CochraneCochrane Review: Aromatherapy for dementia2020CochraneCochrane Review: Avatar Therapy for people with schizophrenia or related disorders2020CochraneCochrane Review: Behavioural activation therapy for depression in adults with non-communicable diseases2020CochraneCochrane Review: Benzodiazepines for treatment of patients with delirium excluding those who are cared for in an intensive care unit2020CochraneCochrane Review: Cognitive behavioural therapy for anxiety disorders in children and adolescents2020CochraneCochrane Review: Cognitive behavioural therapy for tinnitus2020CochraneCochrane Review: Cognitive-behavioural therapy (CBT) interventions for young people aged 10 to 18 with harmful sexual behaviour2020CochraneCochrane Review: Computerised cognitive training for 12 or more weeks for maintaining cognitive function in cognitively healthy people in late life2020CochraneCochrane Review: Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders2020CochraneCochrane Review: Drug therapy for delirium in terminally ill adults2020CochraneCochrane Review: Interventions for the management of obesity in people with bipolar disorder2020CochraneCochrane Review: Interventions to improve return to work in depressed people2020CochraneCochrane Review: Interventions to support the resilience and mental health of frontline health and social care professionals during and after a2020CochraneCochrane Review: Maintenance agonist treatments for opiate-dependent pregnant women2020CochraneCochrane Review: Maintenance treatment with antipsychotic drugs for schizophrenia2020CochraneCochrane Review: Pharmacological interventions for antisocial personality disorder2020CochraneCochrane Review: Pharmacological treatment of depression in people with a primary brain tumour2020CochraneCochrane Review: Pharmacological, psychological and non-invasive brain stimulation interventions for preventing depression after stroke2020CochraneCochrane Review: Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke2020CochraneCochrane Review: Pharmacotherapies for sleep disturbances in dementia2020CochraneCochrane Review: Psychological and social interventions for the prevention of mental disorders in people living in low- and middle-income countries affected by humanitarian crises2020CochraneCochrane Review: Psychological interventions for antisocial personality disorder2020CochraneCochrane Review: Psychological interventions for psychosis in adolescents2020CochraneCochrane Review: Psychological therapies for people with borderline personality disorder2020CochraneCochrane Review: Psychological therapies for women who experience intimate partner violence2020CochraneCochrane Review: Psychosocial interventions for conversion and dissociative disorders in adults2020CochraneCochrane Review: Simulated presence therapy for dementia2020CochraneCochrane Review: Specialised early intervention teams (extended time) for recent-onset psychosis2020CochraneCochrane Review: Specialised early intervention teams for recent-onset psychosis2020CochraneCochrane Review: Video calls for reducing social isolation and loneliness in older people: a rapid review2020DGPPNS3-Leitlinie Posttraumatische Belastungsstörung (PTBS) - Interessenkonflikte2020DGPPN (Deutsche Gesellschaft für Psychiatrie und Psychotherapie)S3-Leitlinie Diagnostik und Therapie Bipolarer Störungen2020IQWiGIQWiG HT17-05: Angststörungen: Führt der ergänzende Einsatz der Eye Movement Desensitization and Reprocessing Therapie bei psychotherapeutischen2020IQWiGIQWiG HT18-04: Herbst-Winter-Depression: Führen nichtmedikamentöse Verfahren wie Licht- und Vitamintherapie zu besseren Ergebnissen?2020NICENG181: Rehabilitation for adults with complex psychosis2020NICENICE Guideline on Bipolar Disorder2020USPSTFPrimary Care Interventions for Prevention and Cessation of Tobacco Use in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.2020USPSTFPrimary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults: US Preventive Services Task Force Recommendation Statement.2020USPSTFScreening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement.2020AkdÄAkdÄ: Information der Britischen Arzneimittelbehörde zu Montelukast: Risiko von neuropsychiatrischen Reaktionen2019AkdÄAkdÄ: Rote-Hand-Brief zu Belimumab (Benlysta®): Erhöhtes2019AkdÄAkdÄ: Rote-Hand-Brief zu hormonellen Kontrazeptiva: Neuer2019AWMFS3-Leitlinie Pathologisches Glücksspiel und Glücksspielstörung2019CochraneCochrane Review: Acetylsalicylic acid (aspirin) for schizophrenia2019CochraneCochrane Review: AD-8 for detection of dementia across a variety of healthcare settings2019CochraneCochrane Review: Addenbrooke's Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment2019CochraneCochrane Review: Adjuvant therapy with antidepressants for the management of inflammatory bowel disease2019CochraneCochrane Review: Animal-assisted therapy for dementia2019CochraneCochrane Review: Antidepressants plus benzodiazepines for adults with major depression2019CochraneCochrane Review: Baclofen for alcohol withdrawal2019CochraneCochrane Review: Beginning reading interventions for children and adolescents with intellectual disability2019CochraneCochrane Review: Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses2019CochraneCochrane Review: Benzodiazepines versus placebo for panic disorder in adults2019CochraneCochrane Review: Cognitive training for people with mild to moderate dementia2019CochraneCochrane Review: Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults2019CochraneCochrane Review: Computerised cognitive training for maintaining cognitive function in cognitively healthy people in midlife2019CochraneCochrane Review: Computerised cognitive training for preventing dementia in people with mild cognitive impairment2019CochraneCochrane Review: Couple and family therapies for post-traumatic stress disorder (PTSD)2019CochraneCochrane Review: Electroconvulsive therapy for treatment-resistant schizophrenia2019CochraneCochrane Review: Family therapy approaches for anorexia nervosa2019CochraneCochrane Review: Haloperidol discontinuation for people with schizophrenia2019CochraneCochrane Review: Human resource management training of supervisors for improving health and well-being of employees2019CochraneCochrane Review: Inpatient versus outpatient care, partial hospitalisation and waiting list for people with eating disorders2019CochraneCochrane Review: Interventions for female drug-using offenders2019CochraneCochrane Review: Interventions for preventing delirium in older people in institutional long-term care2019CochraneCochrane Review: Interventions for prodromal stage of psychosis2019CochraneCochrane Review: Light therapy for preventing seasonal affective disorder2019CochraneCochrane Review: Lithium for acute mania2019CochraneCochrane Review: Memantine for dementia2019CochraneCochrane Review: Mindfulness-based stress reduction for women diagnosed with breast cancer2019CochraneCochrane Review: Modafinil for people with schizophrenia or related disorders2019CochraneCochrane Review: Multiple session early psychological interventions for the prevention of post-traumatic stress disorder2019CochraneCochrane Review: Peer support for people with schizophrenia or other serious mental illness2019CochraneCochrane Review: Pharmacological interventions for the treatment of delirium in critically ill adults2019CochraneCochrane Review: Pharmacotherapies for cannabis dependence2019CochraneCochrane Review: Pharmacy-based management for depression in adults2019CochraneCochrane Review: Present-centered therapy (PCT) for post-traumatic stress disorder (PTSD) in adults2019CochraneCochrane Review: Psychological interventions for co-occurring depression and substance use disorders2019CochraneCochrane Review: Psychological therapies for preventing seasonal affective disorder2019CochraneCochrane Review: Psychological therapies for the prevention of migraine in adults2019CochraneCochrane Review: Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease2019CochraneCochrane Review: Psychosocial interventions for informal caregivers of people living with cancer2019CochraneCochrane Review: Psychosocial interventions for people with both severe mental illness and substance misuse2019CochraneCochrane Review: Psychosocial interventions for preventing and treating depression in dialysis patients2019CochraneCochrane Review: Second-generation antidepressants for preventing seasonal affective disorder in adults2019CochraneCochrane Review: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery2019CochraneCochrane Review: Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years2019CochraneCochrane Review: Systematic screening and assessment of psychosocial well-being and care needs of people with cancer2019CochraneCochrane Review: Treatments for primary delusional infestation2019CochraneCochrane Review: Yoga as part of a package of care versus non-standard care for schizophrenia2019DGPPNS2k-Leitlinie Einwilligung von Menschen mit Demenz in medizinische Maßnahmen2019DGPPNS3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen2019DGPPNS3-Leitlinie Kindesmisshandlung, -missbrauch und -vernachlässigung (Kinderschutzleitlinie) - Evidenzbericht2019G-BAG-BA Nutzenbewertung: Lisdexamfetamindimesilat (neues Anwendungsgebiet: Aufmerksamkeitsdefizit-Hyperaktivitäts-Störungen, ≥ 18 Jahre)2019G-BAG-BA Nutzenbewertung: Melatonin2019IQWiGIQWiG A19-40: Lisdexamfetamin (ADHS) - Nutzenbewertung gemäß § 35a SGB V2019IQWiGIQWiG HT17-03: Suizidale Krisen bei unipolarer Depression: Welchen Einfluss haben nicht medikamentöse Maßnahmen auf deren Bewältigung2019NICENICE Guideline on Delirium2019NICENICE NG134: Depression in children and young people: identification and management2019SIGNSIGN 157: Risk Reduction and Management of Delirium2019USPSTFInterventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement.2019AkdÄAkdÄ: Information der FDA zu Lamotrigin: Überschießende Reaktion des Immunsystems.2018AWMFS3-Leitlinie ADHS bei Kindern, Jugendlichen und Erwachsenen (AWMF 028-045, 2018)2018BfArMSuizidalität als mögliche Folge einer Depression unter der Anwendung hormoneller Kontrazeptiva2018DGPPNS3-Leitlinie Verhinderung von Zwang: Prävention und Therapie aggressiven Verhaltens - Praxisversion2018Diabetes CanadaDiabetes Canada Chapter 18: Diabetes and Mental Health2018G-BAG-BA Nutzenbewertung: Cariprazin (Schizophrenie)2018IQWiGIQWiG A18-25: Cariprazin (Schizophrenie) - Nutzenbewertung gemäß § 35a SGB V2018IQWiGIQWiG A18-50: Cariprazin (Schizophrenie) - Addendum zum Auftrag A18-252018IQWiGIQWiG S16-05: Screening auf Depression2018NICENG105: Preventing suicide in community and custodial settings2018NICENG93: Learning disabilities and behaviour that challenges: service design and delivery2018NICENICE Guideline on ADHD2018NICENICE Guideline on Dementia2018NICENICE NG116: Post-traumatic stress disorder (PTSD)2018NICENICE NG87: Attention deficit hyperactivity disorder: diagnosis and management2018USPSTFScreening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.2018USPSTFUSPSTF: Unhealthy Alcohol Use in Adults: Screening and Brief Intervention (Grade B, 2018)2018AkdÄAkdÄ: Information zu Clozapin: Britische Arzneimittelbehörde2017AkdÄAkdÄ: Informationsbrief zu Arzneimitteln, die Valproat und2017AkdÄAkdÄ: Rote-Hand-Brief zu Haldol® (Tabletten, Tropfen zum2017AWMFS3-Leitlinie Langzeitanwendung von Psychopharmaka bei depressiven und Angststörungen2017AWMFS3-Leitlinie Psychosomatik bei chronischen Schmerzstörungen2017DGPPNS3-Leitlinie Fibromyalgiesyndrom2017IQWiGIQWiG N14-02: Systemische Therapie bei Erwachsenen als Psychotherapieverfahren2017IQWiGIQWiG V15-02: Leitliniensynopse für ein DMP Depressionen2017NICECG100: Alcohol-use disorders: diagnosis and management of physical complications2017NICECG158: Antisocial behaviour and conduct disorders in children and young people: recognition and management2017NICENG64: Drug misuse prevention: targeted interventions2017NICENICE Guideline on Eating Disorders2017NICENICE NG69: Eating disorders: recognition and treatment2017AkdÄAkdÄ Bekanntgabe: Medikamentös-toxische Kardiomyopathie mit kardiogenem Schock unter Quetiapin2016NICECG155: Psychosis and schizophrenia in children and young people: recognition and management2016NICENG54: Mental health problems in people with learning disabilities: prevention, assessment and management2016NICENG55: Harmful sexual behaviour among children and young people2016NICENG58: Coexisting severe mental illness and substance misuse: community health and social care services2016SIGNSIGN 145: Assessment, Diagnosis and Interventions for Autism Spectrum Disorders2016WHOWHO mhGAP Intervention Guide for Mental Health (Version 2.0)2016G-BAG-BA Nutzenbewertung: Vortioxetin (Major Depression)2015IQWiGIQWiG A14-42: Lurasidon - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2015IQWiGIQWiG A15-16: Vortioxetin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2015IQWiGIQWiG A15-37: Vortioxetin (Addendum zum Auftrag A15-16)2015NICENG10: Violence and aggression: short-term management in mental health, health and community settings2015NICENG11: Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges2015NICENG26: Children’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care2015NICENG32: Older people: independence and mental wellbeing2015AWMFS3-Leitlinie Behandlung von Adipositas2014AWMFS3-Leitlinie Psychosomatik in der Gastroenterologie2014G-BAG-BA Nutzenbewertung: Lurasidon (Schizophrenie)2014G-BAG-BA Nutzenbewertung: Nalmefen (Reduktion des Alkoholkonsums bei Alkoholabhängigkeit)2014IQWiGIQWiG A14-30: Nalmefen - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)2014NICENICE CG178: Psychosis and schizophrenia in adults: prevention and management2014NICENICE CG185: Bipolar disorder: assessment and management2014NICENICE CG192: Antenatal and postnatal mental health2014NICENICE Guideline on Psychosis and Schizophrenia2014G-BAG-BA Nutzenbewertung: Lisdexamfetamindimesilat (Aufmerksamkeitsdefizit-Hyperaktivitäts-Störungen, ≥ 6 bis < 18 Jahre)2013IQWiGIQWiG G09-01: Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen2013IQWiGIQWiG GA10-01: Pilotstudie Analytic Hierarchy Process in der Indikation Majore Depression2013NICECG159: Social anxiety disorder: recognition, assessment and treatment2013NICECG77: Antisocial personality disorder: prevention and management2013SIGNSIGN 131: Management of schizophrenia2013WHOGuidelines for the management of conditions that are specifically related to stress2013AWMFS3-Leitlinie Umgang mit Patienten mit nicht-spezifischen, funktionellen und somatoformen Körperbeschwerden2012AkdÄAkdÄ Bekanntgabe: Abhängigkeitspotenzial von Pregabalin (Lyrica®)2011IQWiGIQWiG A05-20C: Bupropion, Mirtazapin und Reboxetin zur Behandlung der Depression2011NICECG136: Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services2011NICENICE CG113: Generalised anxiety disorder and panic disorder in adults2011NICENICE Guideline on Substance Misuse2011AASLDAASLD Practice Guidelines: Alcoholic Liver Disease2010IQWiGIQWiG A05-20A: Selektive Serotonin- und Noradrenalin-Wiederaufnahme-Hemmer (SNRI) zur Behandlung der Depression2010AkdÄAkdÄ Bekanntgabe: Akute psychotische Reaktion nach Amoxicillin/Clavulansäure2009AkdÄAkdÄ Bekanntgabe: Psychiatrische Erkrankungen als unerwünschte Arzneimittelwirkung von Mirena®2009IQWiGIQWiG GA09-01: Leitliniensynopse zum Thema "Depression"2009NICECG91: Depression in adults with a chronic physical health problem: recognition and management2009NICENICE NG53: Borderline personality disorder: recognition and management2009BfArMAntidepressiva: Erhöhtes Risiko zu suizidalem Verhalten bei Erwachsenen unter 25 Jahren2008BfArMRote-Hand-Brief zu Acomplia®: Europäische Arzneimittelagentur empfiehlt Anwendungsbeschränkungen2007NICECG51: Drug misuse in over 16s: psychosocial interventions2007BfArMAntidepressiva: Wissenschaftliche Neubewertung der SSRI/SNRI abgeschlossen - Neue Warnhinweise auf suizidales Verhalten bei Kindern und Jugendlichen2005NICENICE CG31: Obsessive-compulsive disorder and body dysmorphic disorder2005NICENICE Guideline on OCD2005SIGNSIGN 82: Bipolar affective disorder2005BfArMParoxetin: Als Antidepressivum bei unter 18-Jährigen jetzt kontraindiziert2004
Und über 3.000 weitere Leitlinien aus AWMF, NVL, RKI, WHO, NICE u.a.
Häufige Fragen
Ja, ClariMed liefert leitlinienbasierte Informationen zu Wechselwirkungen, Dosisanpassungen und Kontraindikationen. Suchen Sie z.B. nach "Valproat Lamotrigin Aufdosierung" oder "Antidepressiva Stillzeit".
Ja, ClariMed enthält Embryotox-Empfehlungen zur Arzneimittelsicherheit in Schwangerschaft und Stillzeit, zusätzlich zu AWMF und DGPPN-Leitlinien.
Weitere Fachgebiete
Leitlinien-Suche starten
Durchsuchen Sie Psychiatrie-Leitlinien und tausende weitere Quellen — kostenlos und ohne Anmeldung.
Jetzt suchenStand: 22. Mai 2026